BRTX · BioRestorative Therapies, Inc.
$0.22
-0.01 (-2.40%)
At close · Aug 21
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on these conditions, we believe we do not have sufficient cash for at least twelve months after the issuance date of the financial statements included in this Quarterly Report which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$5.49M
Shares
25.48M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Lance Alstodt | Chief Executive Officer | $1,314,583 |
| Francisco Silva | VP, Research and Development | $1,227,083 |
| Robert Kristal | Chief Financial Officer | $683,752 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Lance Alstodt | Chief Executive Officer | $1,254,167 |
| Francisco Silva | VP, Research and Development | $1,204,167 |
| Robert Kristal | Chief Financial Officer | $618,124 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lance Alstodt | Chief Executive Officer | $452,364 |
| Francisco Silva | VP, Research and Development | $427,364 |
| Robert Kristal | Chief Financial Officer | $175,000 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Lance Alstodt | Chief Executive Officer | $21,341,489 |
| Francisco Silva | VP, Research and Development | $21,325,864 |
| Robert Kristal | Chief Financial Officer | $82,383 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Francisco Silva | VP, Research and Development | $207,553 |
| Mark Weinreb | Chief Executive Officer | $179,172 |
| Lance Alstodt | Chief Executive Officer | $64,317 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Mark Weinreb | Chief Executive Officer | $372,352 |
| Lance Alstodt | Chief Executive Officer | $350,000 |
| Francisco Silva | VP, Research and Development | $287,500 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Katharyn Field | officer of the Company | Appointed | 2026-07-16 |
| Robert Kristal | Chief Financial Officer | Resigned | 2026-07-16 |
| Lance Alstodt | Chairman of the Board | Resigned | 2026-07-16 |
| Lance Alstodt | President | Resigned | 2026-07-16 |
| Lance Alstodt | President, Chief Executive Officer and Chairman of the Board | Resigned | 2026-07-16 |
| David Rosa | director | Resigned | 2026-07-16 |
| Patrick F. Williams | director | Resigned | 2026-06-12 |
| Nickolay Kukekov | director | Resigned | 2026-06-12 |
| Francisco Silva | director | Resigned | 2026-06-12 |
| David Rosa | director | Appointed | 2021-11-08 |
| Patrick F. Williams | director | Appointed | 2021-11-08 |
| Robert E. Kristal | Chief Financial Officer | Appointed | 2021-11-08 |
| Nickolay Kukekov | director | Appointed | 2021-03-19 |
| Francisco Silva | director | Appointed | 2020-11-20 |
| Lance Alstodt | director | Appointed | 2020-11-20 |
| Lance Alstodt | Chairman of the Board | Appointed | 2020-11-20 |
| Lance Alstodt | President, Chief Executive Officer | Appointed | 2020-11-20 |
| Robert B. Catell | director | Resigned | 2020-11-20 |
| Paul Jude Tonna | director | Resigned | 2020-11-20 |
| A. Jeffrey Radov | director | Resigned | 2020-11-20 |
| Mark Weinreb | director | Resigned | 2020-11-20 |
| Mark Weinreb | Chairman of the Board | Resigned | 2020-11-20 |
| Mark Weinreb | President, Chief Executive Officer and Chairman of the Board | Resigned | 2020-11-20 |
| Lance Alstodt | Executive Vice President and Chief Strategy Officer | Terminated | 2020-02-26 |
| Charles S. Ryan | director | Resigned | 2020-01-10 |
Key facts
CIK
1505497
CUSIP
090655606
13F (30d)
22 filings
22 filers
Visit website
Investor relations